VANDA PHARMACEUTICALS INC. (NASDAQ:VNDA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

VANDA PHARMACEUTICALS INC. (NASDAQ:VNDA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02.

Press release of Vanda Pharmaceuticals Inc. dated April24, 2019.
Story continues below

Vanda Pharmaceuticals Inc. Exhibit
EX-99.1 2 d724895dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Vanda Pharmaceuticals Appoints Phaedra Chrousos to Board of Directors WASHINGTON,…
To view the full exhibit click here

About VANDA PHARMACEUTICALS INC. (NASDAQ:VNDA)

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. The Company offers HETLIOZ (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). The Company offers Fanapt (iloperidone) for the treatment of schizophrenia. Additionally, its distribution partners launched Fanapt in Israel and Mexico. Tradipitant (VLY-686) is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. It is indicated for the treatment of CNS Disorders.

An ad to help with our costs